Is cancer-related, direct-to-consumer advertising beneficial?—No.
In the current communications era, cancer medications, cancer-related genetic testing, and even cancer centers are often marketed directly to the public. While there is little evidence so far that it generates inappropriate treatment recommendations in oncology,1 cancer-related, direct-to-consumer advertising (CR-DTCA) is prone to cause harm in many other ways. These include potentially fostering patient misinterpretations of expected efficacy and toxic effects of drugs with concomitant harm to the patient-physician therapeutic relationship; encouraging patient interest in new drugs when their toxic effects are not fully appreciated; and failing to present alternative treatment approaches that may be less toxic or costly.
Schnipper LE, Abel GA. Direct-to-Consumer Drug Advertising in Oncology Is Not Beneficial to Patients or Public Health. JAMA Oncol. 2016;2(11):1397–1398. doi:10.1001/jamaoncol.2016.2463
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: